OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Martin-Broto on the Ongoing Research of MDM2 Agonists in Soft Tissue Sarcoma

June 15th 2022

Javier Martin-Broto, MD, PhD, discusses the ongoing research of MDM2 agonists in patients with soft tissue sarcoma.

Dr. Kahn on Next Steps on Examining Racial Disparities in GI Cancer

June 15th 2022

Sajid A Khan MD, FACS, FSSO, discusses next steps in examining racial disparities in gastrointestinal tract cancer.

Dr. Raje on Current CAR T-Cell Therapies in Multiple Myeloma

June 15th 2022

Noopur Raje, MD, discusses current CAR T-cell therapies in multiple myeloma.

Dr. Packiam on Safety of Cabazitaxel/Gemcitabine Plus Pembrolizumab in Urothelial Carcinoma

June 15th 2022

Vignesh Packiam, MD, discusses the adverse effects associated with cabazitaxel and gemcitabine with pembrolizumab in patients who are unresponsive to docetaxel with non-muscle invasive urothelial carcinoma.

Dr. Sandhu on the Safety Data Seen in the MAGNITUDE Trial in Prostate Cancer

June 14th 2022

Shahneen Sandhu, MD, discusses the safety data seen in the phase 3 MAGNITUDE trial in metastatic prostate cancer.

Dr. Lin on the Advantage of Elacestrant in ESR1-Mutated Breast Cancer

June 14th 2022

Nancy U. Lin, MD, discusses the advantage of the oral selective estrogen receptor degrader, elacestrant, in ESR1-mutated breast cancers.

Dr. Hamilton on the EMERALD Trial in ER-Positive/HER2-Negative Breast Cancer

June 14th 2022

Erika P. Hamilton, MD, discusses the updated analysis of the phase 3 EMERALD trial in estrogen receptor–positive, HER2-negative breast cancer.

Dr. Gisslinger on EFS Rates With Ropeginterferon Alfa-2b in Polycythemia Vera

June 13th 2022

Heinz Gisslinger, MD, discusses the 6-year event-free survival data from the phase 3 PROUD-PV and CONTI-PV trials.

Dr. Short on Ponatinib and Blinatumomab in Philadelphia Chromosome–Positive ALL

June 13th 2022

Nicholas J. Short, MD, discusses updated results from a single-arm phase 2 study investigating ponatinib plus blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Dr. Al-Sawaf on the 5-Year Results of the CLL14 Trial in CLL

June 12th 2022

Othman Al-Sawaf, MD, discusses the 5-year follow up data from the phase 3 CLL14 trial (NCT02242942) in patients with previously untreated chronic lymphocytic leukemia (CLL) with preexisting conditions.

Dr. Mascarenhas on Updates from the MANIFEST Trial in Myelofibrosis

June 11th 2022

John O. Mascarenhas, MD, discusses updates from the phase 2 MANIFEST trial in patients with myelofibrosis.

Dr. Yilmaz on the Benefit of Quizartinib Triplet in AML

June 11th 2022

Musa Yilmaz, MD, discusses composite complete remission and bone marrow transplant rates observed in a phase 1/2 trial in patients with FLT3-ITD–mutated acute myeloid leukemia.

Dr. Eyre on the Design of the BRUIN-MCL-321 Trial in MCL

June 10th 2022

Toby Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, discusses the design and the rationale of the phase 3 BRUIN-MCL-321 trial in mantle cell lymphoma.

Dr. Cordoba on the Efficacy of Epcoritamab in DLBCL

June 10th 2022

Raul Cordoba, MD, PhD, discusses efficacy data with epcoritamab observed in the phase 1/2 EPCORE NHL-2 trial in relapsed/refractory diffuse large B-cell lymphoma.

Dr. Stein on the SELECT-AML-1 Trial in Newly Diagnosed AML

June 10th 2022

Eytan M. Stein, MD, discusses the phase 2 SELECT-AML-1 trial in patients with newly diagnosed acute myeloid leukemia.

Dr. Stein on the KOMET-001 Trial in Relapsed/Refractory AML

June 10th 2022

Eytan M. Stein, MD, discusses the phase 1/2 KOMET-001 trial in relapsed/refractory acute myeloid leukemia.

Dr. Castillo on the CLOVER-WaM Trial in Waldenström Macroglobulinemia

June 10th 2022

Jorge J. Castillo, MD, discusses the phase 2 CLOVER WaM trial in Waldenström macroglobulinemia.

Dr. Velcheti on the Safety of Nemvaleukin in Solid Tumors

June 7th 2022

Vamsidhar Velcheti, MD, discusses the safety of nemvaleukin alfa in patients with advanced solid tumors in the phase 1/2 ARTISTRY-1 trial.

Dr. Botta on the Evaluation of CT041 in Gastric and Pancreatic Cancer

June 7th 2022

Gregory Botta, MD, PhD, discusses the evaluation of CT041 in patients with advanced gastric and pancreatic cancers in a phase 1b trial.

Dr. Rao on the Rationale of the CASPAR Trial in mCRPC

June 7th 2022

Arpit Rao, MD, discusses the rationale and importance of the phase 3 CASPAR trial in castration-resistant prostate cancer.